Multiple target-based combination therapy of galantamine, memantine and lycopene for the possible treatment of Alzheimer's disease.
Alzheimer’s disease
Antioxidant
Lycopene
Memantine
Neuroinflammation
Journal
Medical hypotheses
ISSN: 1532-2777
Titre abrégé: Med Hypotheses
Pays: United States
ID NLM: 7505668
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
14
04
2020
accepted:
22
05
2020
pubmed:
1
6
2020
medline:
15
5
2021
entrez:
1
6
2020
Statut:
ppublish
Résumé
Alzheimer's disease is type of dementia in which cognitive functions get declined. More than 50 million people are affected by this disease across the world. Many clinical and preclinical studies have been conducted on the treatment of AD but very limited number of drugs have found a clinical application. Because regeneration of neuron is a complicated process due to the involvement of multiple pathways, a combination of drugs that can work through multiple pathways could prove to be effective in treating AD. Based on prior studies and different mechanisms involved in the treatment, a new hypothesis has been proposed that a combination of galantamine, memantine and lycopene is anticipated to produce better activity as compared to the current therapies available in market for the treatment of this disease.
Identifiants
pubmed: 32474382
pii: S0306-9877(20)30806-9
doi: 10.1016/j.mehy.2020.109879
pii:
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Indans
0
Piperidines
0
Galantamine
0D3Q044KCA
Donepezil
8SSC91326P
Lycopene
SB0N2N0WV6
Memantine
W8O17SJF3T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109879Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.